Drugdiscovery >> Drugs >> News
4332
Views
Europe-wide cancer research collabortion is announced - drugdiscovery.com
Europe-wide cancer research collabortion is announced - drugdiscovery.com


European institutions announced a collaboration for cancer research. CRT and Nuevolution says, this going to help to delvelop a trustable cure for as wide range of cancer types.
Read More >>


Tags: CRT, Nuevolution, cancer, drug - January 27, 2014
Related Articles
7374
Views
Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe
The European Commission has granted marketing authorization for afatinib, used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC Read More >>

Tags: Giotrif, afatinib, locally advanced, metastatic, non-small cell lung cancer, NSCLC, EGFR mutation, EU, Europe

6307
Views
First biosimilar mAb therapy approved in Europe First biosimilar mAb therapy approved in Europe
Hospira’s Inflectra, monoclonal antibody (mAb) therapy, a biosimilar to Remicade (infliximab), has been approved by the European Commission (EC) for the treatment of inflammatory conditions includin Read More >>

Tags: Hospira, Inflectra, infliximab, Remicade, biosimilar, monoclonal antibody, inflamatory conditions, treatment, Europe

3963
Views
Generic version of Antara is announced Generic version of Antara is announced
Dr. Reddy’s Laboratories announced the generic version of Antara. Fenofibrate Capsules are used to treat Primary Hypercholesterolemia and Mixed Dyslipidemia. Read More >>

Tags: Primary Hypercholesterolemia, Mixed Dyslipidemia, Fenofibrate Capsules, drug discovery, generic drugs, generig drug marketing

2526
Views
Lojuxta authorised in Europe Lojuxta authorised in Europe
The European Commission has authorised Lojuxta, by Aegerion Pharmaceuticals, for the treatment of patients with life threatening, rare inherited disease called homozygous familial hypercholesterolaemi Read More >>

Tags: Lojuxta, Aegerion Pharmaceuticals, homozygous familial hypercholesterolaemia

10840
Views
Another Sanofi MS drug approved in EU Another Sanofi MS drug approved in EU
After Aubagio, Lemtrada - another Sanofi’s drug for treatment of multiple sclerosis has been approved by the European Commission. Read More >>

Tags: multiple sclerosis, Europe, new drug, Aubagio, Lemtrada

6453
Views
Remicade Copies Approved in Europe Remicade Copies Approved in Europe
J&J’s Remicade, a drug for arthritis, will have cheaper versions made and sold by two other companies in Europe by 2014. Read More >>

Tags: Remicade, Arthritis, Celltrion, Hospira

12436
Views
New drug for treating myeloma approved in Europe New drug for treating myeloma approved in Europe
The European Commission has granted approval for Celgene’s drug pomalidomide for the treatment of relapsed and refractory multiple myeloma, in combination with dexamethasone. The marketing name of Read More >>

Tags: Celgene, pomalidomide, multiple myeloma,Imnovid,the European Commission approval

4098
Views
Three New European Marketing Authorizations for Takeda Three New European Marketing Authorizations for Takeda
The European Commission has granted Marketing Authorization (MA) for Vipidia (alogliptin) for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies and for the fixed-dos Read More >>

Tags: Takeda, EMA, EC, Europe, marketing authorisation, type 2 diabetes, Vipidia, alogliptin, Vipdoment, Incresync

8501
Views
Takeda's schizophrenia drug lurasidone approved in Swiss Takeda's schizophrenia drug lurasidone approved in Swiss
This is the first approval in Europe for lurasidone, which is already marketed as Latuda for schizophrenia and bipolar depression in the US and Canada. Read More >>

Tags: lurasidone, latuda, drug, schizophrenia, bipoloar disorder, Swiss, approval, Europe

4190
Views
Orexigen seeks approval for obesity drug Contrave in EU Orexigen seeks approval for obesity drug Contrave in EU
If approved after an eagerly-anticipated interim analysis of a cardiovascular outcomes trial called the Light study, the drug might be launched in EU in early 2015. Contrave (naltrexone/bupropion) i Read More >>

Tags: Orexigen, EU, Europe, Contrave, drug, obesity, depression, cravings

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013